CRISPR-Cas9 engineering of CAR-T cells: Can non-viral nanoparticles unlock safer and scalable genome editing?

iScience 2026 Open access

Read full text
Authors: Bruna My, Andrea Lia, Ludovica Rizzo, Gabriele Maiorano, Antonio Galeone, Ilaria Elena Palamà, Giuseppe Gigli
DOI: 10.1016/j.isci.2026.115422
Cited by: 2
References: 142

Abstract

T cell programming; and outline genome-engineering strategies organized by therapeutic goals. We highlight feasibility trade-offs and discuss how nanoparticles could enable transient, non-viral delivery of genome editors, while noting that robust T cell targeting and standardized potency/safety assays remain key bottlenecks.

Fields of Study & Subjects

CRISPR and Genetic Engineering CAR-T cell therapy research Virus-based gene therapy research

Publication details

Journal / source
iScience
Publisher
Elsevier BV
Volume
29
Issue
5
Pages
115422–115422
Publication date
20 March 2026
Language
EN